

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **King International Investment Limited**

**帝王國際投資有限公司**

*(formerly known as Life Healthcare Group Limited 蓮和醫療健康集團有限公司)*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 928)**

## **VOLUNTARY ANNOUNCEMENT FORMATION OF A JOINT VENTURE**

This announcement is made by King International Investment Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, the purpose of which is to keep the shareholders and potential investors of the Company informed of the latest business developments of the Group.

### **FORMATION OF THE JOINT VENTURE**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 7 July 2025, the Company or its designated subsidiary, Angeleo (Shenzhen) Synthetic Biology Industrial Development Co., Ltd.\* (安各洛(深圳)合成生物實業發展有限公司) (“**Angeleo Synthetic**”), Angeleo (Shenzhen) Biotechnology Co., Ltd.\* (安各洛(深圳)生物技術有限公司) (“**Angeleo Biotechnology**”), Shenzhen Super Oxygen Era Biotechnology Co., Ltd.\* (深圳超氧紀元生物科技股份有限公司) (“**Shenzhen Super Oxygen**”) and Wang Xiaofeng (the “**JV Partners**”), established a joint venture in the PRC (the “**Joint Venture**”). The Joint Venture is held as to 34% by the Company, 63% by the JV Partners. The Company and the JV Partners have contributed HK\$3,400,000 and HK\$6,300,000 in cash or asset in proportion to their respective equity interests to the share capital of the Joint Venture, respectively. No further capital contribution commitment for the Joint Venture is expected to be made by the Group as at the date of this announcement. The Joint Venture will be accounted for as an investment in an associated company in the consolidated financial statements of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company considers that the formation of Joint Venture provides a valuable opportunity to the parties to leverage their respective resources and expertise and create mutual benefits and synergy to each other. It will achieve more efficient operations and enhance product marketing and therefore further promote the healthcare business of the Group. Therefore, the Board is of the view that the formation of Joint Venture is in the interest of the Company and its shareholders as a whole.

## REASONS FOR AND BENEFITS OF THE FORMATION OF THE JOINT VENTURE

To seize opportunities in the global biopharmaceutical market, the Board has resolved to add a new Superoxide Dismutase Core business segment (the “SOD”). SOD possesses a unique scientific mechanism, demonstrating effective free radical scavenging capabilities, cellular repair mechanisms, and anti-inflammatory regulation properties. It has core advantages in the industrialization field, enabling long-term preservation of activity at room temperature without degradation and significantly enhancing output through fermentation technology, thus leading in production efficiency.

This segment can be applied in strategic areas such as high-end medical aesthetics, functional foods, and specialized medical applications. It comes with intellectual property barriers, including a core patent group covering production processes and exclusive equipment design patents. The addition of the SOD business segment is expected to open up a growth trajectory in the biopharmaceutical sector, empower the upgrade of existing consumer businesses, and build a technology-driven valuation system.

## LISTING RULES IMPLICATIONS

As the highest applicable percentage ratio (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)) in respect of the formation of the Joint Venture is less than 5%, the formation of the Joint Venture does not constitute a notifiable transaction for the Company under Chapter 14 of the Listing Rules. The Company will make further announcement in compliance with the relevant requirements under the Listing Rules as and when necessary.

**As the formation of Joint Venture may or may not proceed, the Company’s shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**King International Investment Limited**  
**Wang Mengyao**  
*Executive Director*

Hong Kong, 7 July 2025

*As at the date of this announcement, the Board comprises:*

*Executive Directors:*

Mr. Leng Yueyingtan (*Chairman*)  
Mr. Wang Mengyao  
Mr. Man Wai Lun  
Mr. Li Li

*Independent non-executive Directors:*

Mr. Lou Tao  
Mr. Wang Zhenyu  
Mr. Liu Zhong

\* *The English translation of the Chinese name is for information purpose only and should not be regarded as the official English translation of such Chinese name.*